Intrahepatic cholangiocarcinoma is an aggressive, often fatal, malignancy that arises from the bile ducts. As it often presents with metastatic disease, surgery has limited utility. However, in some cases, neoadjuvant chemotherapy has provided the necessary reduction in tumor burden to allow for adequate resection. Consequently, new advances in neoadjuvant chemoradiation and targeted therapy are of interest with numerous case reports and small series published routinely; it is challenging to present a large case series or study given the overall rare frequency with which this malignancy is seen. Herein, we aim to summarize the newest advances in both neoadjuvant chemotherapy and targeted immunotherapy.

Michael Ghio

Adarsh Vijay

Annals of Hepato-Biliary-Pancreatic Surgery

Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy

The newest advances in both neoadjuvant chemotherapy and targeted immunotherapy are summarized.

Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
SURGERY	3